General Catalyst

General Catalyst is a venture capital firm established in 2000 and based in San Francisco, California. The firm specializes in early-stage and growth equity investments across various sectors, including consumer, enterprise, fintech, cryptocurrency, and health assurance. By fostering an environment conducive to growth, General Catalyst aims to accelerate the development of innovative ideas and companies. The firm provides mentorship and connects clients with experienced professionals to enhance their potential for success. As a Registered Investment Adviser, General Catalyst has managed a total of eight venture capital funds, accumulating approximately $3.75 billion in capital commitments.

Adrian Abeijon

Investor

Mark Allen

CFO

Neeraj Arora

Managing Director, Investment Team

Juliet Bailin

Principal

Marc Bhargava

Managing Director

Larry Bohn

Managing Director

Niko Bonatsos

Managing Director

Teresa Carlson

President, General Catalyst Institute

Kenneth Chenault

Chairman and Managing Director

Mark Crane

Partner

Joel Cutler

Co-Founder and Managing Director

Christopher Davis

Partner

Kyle Doherty

Managing Director

Nick van Eck

Partner

David Fialkow

Co-Founder and Managing Director

Bill Fitzgerald

Managing Director and COO

Diana Hong

Investor

Mina Hsiang

Associate

Nmachi Jidenma

Partner

Christopher Kauffman

Principal

Zak Kukoff

Principal

Paul Kwan

Managing Director

Karanveer Mohan

Managing Director, Investment Team

Priya Mohan

Partner, Investment Team

Deep Nishar

Managing Director

Dipchand Nishar

Managing Director

Reva Nohria

Investor

Trevor Oelschig

Managing Director

Tyler Olkowski

Investor

David Orfao

Managing Director and Co-Founder

Pranay Orugunta

Healthcare Investor

Mo Punjwani

Associate, Investments

Candace Richardson

Principal

Max Rimpel

Partner

Sam Rosen

Growth Investor

Pranav Singhvi

Partner

Bill Skarinka

Associate

Hemant Taneja

CEO and Managing Director

Alex Tran

Managing Director

Catherine Tu

Partner, Investment Team

Adam Valkin

Managing Director

Elena Viboch

Partner

Andrea Wang

Principal, Early Stage Investment

Nathaniel Levy-Westhead

Partner, Investment Team

Deep Nishar

Managing Director and Member of the Management Committee

Roy Mabrey

Partner, Investment Team

Past deals in Medical

Neko Health

Series B in 2025
Neko Health is a Swedish health-tech company focused on enhancing healthcare through prevention and early detection of diseases. It has developed innovative medical scanning technology that enables comprehensive and non-invasive health data collection, making it accessible and affordable for the general public. By leveraging sensor technology and artificial intelligence, Neko Health aims to reduce the prevalence of common diseases and their associated healthcare costs. The company provides doctors and clinicians with tools for flexible and cost-effective examinations, ultimately aiming to improve the quality of healthcare and promote proactive health management.

Doccla

Series B in 2024
Doccla is a provider of virtual ward services that focuses on shifting patient care from hospitals to home settings. The company partners with care organizations to facilitate early patient discharge and reduce hospital readmissions through remote monitoring using advanced medical devices. By onboarding patients at home with the necessary monitoring equipment, Doccla employs a mobile team of healthcare professionals, including nurses and doctors, to oversee patient care. This approach not only ensures that patients receive timely and effective treatment but also aims to enhance care quality while lowering associated costs. Originally developed as part of a research initiative for the NHS, Doccla's innovative service has been successfully implemented in collaboration with Northampton General Hospital.

Hona AI

Seed Round in 2024
Hona AI is an AI data platform that collects and maintains healthcare history and records of patients.

Transcarent

Series D in 2024
Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Chamber Cardio

Seed Round in 2024
Chamber Cardio is a healthcare platform focused on enhancing cardiovascular health services by facilitating the transition of cardiologists to value-based care. The company provides a range of services, including panel management with real-time updates, financial metrics, and clinical data consolidated into a user-friendly dashboard. Additionally, it offers software support to manage complex patient cases and engages in value-based contracting. This comprehensive approach aims to improve treatment accessibility for patients and streamline operations within the healthcare sector.

Overjet

Series C in 2024
Overjet, Inc. specializes in developing artificial intelligence (AI) software aimed at enhancing dental care. Founded by experts from MIT and Harvard, the company produces clinical optimization and utilization software that analyzes dental clinical data to assess practice performance and identify growth opportunities. Its AI technology is designed to automatically review claims, highlighting instances of over and underutilization to ensure appropriate care at reduced costs. Overjet's FDA-cleared platform is the first objective standard for oral health decision-making, enabling dentists to detect pathologies accurately and communicate effectively with patients. Established in 2018, Overjet is headquartered in Allston, Massachusetts.

Fabric

Series A in 2024
Fabric is a health tech company that enables healthcare providers to deliver faster, higher quality, and more accessible care while reducing costs via consumer-grade patient experiences that automate workflows for staff.

Summa Health

Acquisition in 2024
Summa Health is a comprehensive healthcare provider that focuses on delivering integrated and coordinated care across a network of facilities. This network includes hospitals, community health centers, and a health plan, alongside a physician-hospital organization and a multi-specialty physician organization. Summa Health emphasizes personalized patient-centered care, particularly through its specialized Cancer Centers, which utilize advanced treatment technology and medical expertise to support whole-person healing. Additionally, the organization is involved in research and operates various foundations to enhance healthcare delivery and improve patient outcomes.

Harbor Health

Series A in 2024
Harbor Health is a multi-specialty clinic group based in Austin, Texas, founded in 2022. The organization focuses on delivering personalized, patient-centered healthcare by utilizing technology to enhance the patient experience. Harbor Health offers a collaborative approach to healthcare, working closely with individuals to understand their health goals and providing access to specialists when necessary. The clinic provides a variety of services, including primary care, chronic disease management, behavioral health, and overall wellness. Patients benefit from same-day and virtual appointment options, as well as conveniently located clinics, ensuring that healthcare is accessible and responsive to their needs.

Devoted

Series E in 2023
Devoted Health is a healthcare company focused on enhancing the health and well-being of older Americans by treating each individual with care and compassion. The company offers an integrated healthcare solution that includes Medicare Advantage plans, access to local providers, and the option for virtual and in-home care through Devoted Medical. Their approach includes personalized medical plans and dedicated guides who work closely with physicians to streamline care and minimize unnecessary procedures. By leveraging advanced technology and a robust network of healthcare professionals, Devoted Health aims to provide high-quality, tailored healthcare services to its members.

Layer Health

Seed Round in 2023
Layer Health focuses on resolving the healthcare information problem by utilizing artificial intelligence to execute any clinical, administrative, or research work that involves chart review from unstructured data.

Commure

Venture Round in 2023
Commure, Inc. is a technology company that develops an open platform aimed at healthcare software developers, enabling the creation and deployment of advanced healthcare applications. The platform is built on the open HL7 FHIR standard and offers various features, including an FHIR API server, security framework, event service bus, EHR integration, and a flexible data store. Commure's solutions facilitate the unification of disparate datasets, providing meaningful insights and enhancing performance through intuitive applications. The company collaborates with health systems, digital innovators, and payors to foster a vibrant healthcare ecosystem, ultimately empowering clinicians and staff to improve patient care. Established in 2017, Commure is headquartered in San Francisco, California, with additional offices in Boston, Montreal, and Bogota.

Medeloop

Seed Round in 2023
Medeloop is a pioneering platform that enhances medical research through advanced artificial intelligence and a robust data linkage infrastructure. It integrates and analyzes vast amounts of health data, transforming it into a graph database that provides deeper insights and connectivity. This technology streamlines the clinical research process by offering research hypotheses for underexplored diseases, thereby enabling researchers to publish findings more efficiently. Additionally, Medeloop features a patient-facing application that empowers individuals to monitor their health information and actively contribute to significant medical research. By facilitating collaboration among patients, providers, and researchers, Medeloop aims to accelerate the discovery of biomarkers and potential drug targets, ultimately improving treatment development and saving lives.

Neko Health

Series A in 2023
Neko Health is a Swedish health-tech company focused on enhancing healthcare through prevention and early detection of diseases. It has developed innovative medical scanning technology that enables comprehensive and non-invasive health data collection, making it accessible and affordable for the general public. By leveraging sensor technology and artificial intelligence, Neko Health aims to reduce the prevalence of common diseases and their associated healthcare costs. The company provides doctors and clinicians with tools for flexible and cost-effective examinations, ultimately aiming to improve the quality of healthcare and promote proactive health management.

Memora Health

Venture Round in 2023
Memora Health Inc., founded in 2016 and based in San Francisco, California, develops an enterprise healthcare productivity platform aimed at automating outpatient communication and enhancing care delivery. The company partners with health systems, health plans, and digital health organizations to streamline clinical workflows, allowing clinicians to focus on their primary responsibilities while proactively engaging patients throughout their care journeys. Memora's platform digitizes high-touch processes, intelligently triaging patient-reported data to the relevant care team members and facilitating proactive, two-way communication between patients and providers. By transforming the way care is delivered, Memora Health seeks to make healthcare more actionable, accessible, and continuous.

Maribel Health

Series A in 2023
Maribel Health focuses on developing and operating advanced clinical care models that deliver healthcare services in home and community settings. The company aims to enhance the overall capacity of health systems and improve patient access by offering innovative home-based care solutions. In addition to its care models, Maribel Health provides assessment and planning services for home and community-based care, addressing the specific needs of local markets and healthcare organizations. Through these initiatives, the company seeks to facilitate better healthcare delivery and support the strategic goals of its partners.

Faro Health

Series A in 2023
Faro Health is a developer of a cloud-based medical platform aimed at addressing the complexities of clinical trials. The platform standardizes, automates, and streamlines various challenges associated with clinical studies. By utilizing an integrated clinical development environment, Faro Health simplifies the design and authoring of complex clinical protocols. This system leverages advanced digital protocols to provide intuitive insights during the authoring process, allowing clinical researchers to focus on critical decisions that enhance clinical value while minimizing administrative burdens.

Paradigm

Series A in 2023
Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Vial

Series A in 2022
Vial is a biotech company that focuses on enhancing the efficiency and affordability of clinical trials. By partnering with clinics, Vial transforms them into clinical trial research sites equipped with the necessary technology and infrastructure. The company's platform manages various aspects of clinical trials, including administrative tasks, data entry, patient scheduling and recruitment, invoicing, and compliance. This comprehensive approach allows biotechnology companies to navigate different phases of drug development more effectively while also providing partner clinics with opportunities to increase their revenue. Vial's emphasis on automation and advanced technologies positions it as a key player in the evolution of clinical trial processes.

Vial

Series B in 2022
Vial is a biotech company that focuses on enhancing the efficiency and affordability of clinical trials. By partnering with clinics, Vial transforms them into clinical trial research sites equipped with the necessary technology and infrastructure. The company's platform manages various aspects of clinical trials, including administrative tasks, data entry, patient scheduling and recruitment, invoicing, and compliance. This comprehensive approach allows biotechnology companies to navigate different phases of drug development more effectively while also providing partner clinics with opportunities to increase their revenue. Vial's emphasis on automation and advanced technologies positions it as a key player in the evolution of clinical trial processes.

Maven Clinic

Series E in 2022
Maven Clinic operates an on-demand digital care clinic focused on supporting mothers and families through conception, pregnancy, and postpartum phases. The clinic provides access to video appointments and private messaging with a network of women's and family health practitioners, along with a comprehensive family benefits platform. Its services encompass various tracks, including IVF, egg freezing, pregnancy, postpartum, partner support, adoption, surrogacy, and loss, in addition to career coaching and customized training for human resources professionals. Founded in 2014 and headquartered in New York City, Maven Clinic caters to individuals, employers, and healthcare professionals, aiming to enhance family health and well-being through accessible digital care.

Doccla

Series A in 2022
Doccla is a provider of virtual ward services that focuses on shifting patient care from hospitals to home settings. The company partners with care organizations to facilitate early patient discharge and reduce hospital readmissions through remote monitoring using advanced medical devices. By onboarding patients at home with the necessary monitoring equipment, Doccla employs a mobile team of healthcare professionals, including nurses and doctors, to oversee patient care. This approach not only ensures that patients receive timely and effective treatment but also aims to enhance care quality while lowering associated costs. Originally developed as part of a research initiative for the NHS, Doccla's innovative service has been successfully implemented in collaboration with Northampton General Hospital.

Redesign Health

Series C in 2022
Redesign Health is a company founded in 2018 that focuses on driving innovation in the healthcare sector. It develops technologies, tools, and insights designed to lower barriers to change within the industry. Redesign Health collaborates with exceptional founders to create and support over two dozen companies that have collectively impacted more than ten million lives across various healthcare domains, including cancer care, teleradiology, COVID-19 testing, and metabolic health. By fostering the growth of diverse healthcare solutions, Redesign Health aims to enhance the overall efficiency and effectiveness of healthcare delivery.

Plume Clinic

Series B in 2022
Plume is a health tech company for the transgender community. The company focuses on radically increasing access to care, medication, and products for the trans community, supporting a bold, authentic and healthy lifestyle. Its vision is to make gender-affirming care available to anyone until it transforms healthcare for every trans life.

Homeward

Series B in 2022
Homeward is rearchitecting rural health and care for the 60 million Americans living in rural communities. Homeward employs a multidisciplinary care team, available both virtually and on the ground via mobile care units, with in-home remote monitoring to better connect patients to high-quality, affordable, and comprehensive care. Today, the company partners with Medicare Advantage plans, taking on the full risk of their members to improve outcomes and reduce costs.

Examedi

Series A in 2022
Examedi is a healthcare startup that provides nurse and lab technician services directly at patients' homes for appointments. Examedi connects the availabilities of healthcare providers with patients.

Osmind

Series B in 2022
Osmind is a San Francisco-based public benefit corporation focused on enhancing mental health care through innovative technology and scientific research. The company develops a specialized mental health operating platform that caters to clinicians and researchers working on new treatments for moderate to severe mental health conditions. Its electronic health record technology is tailored for interventional treatment workflows, featuring tools for patient journaling and support with health plan reimbursement. By providing these resources, Osmind aims to empower healthcare professionals to explore novel therapeutic approaches, precision psychiatry, and improve patient care outcomes.

Loop

Series B in 2022
By using data, technology, and high quality medical expertise, we aim to deliver an empathetic people-centric healthcare experience that helps people live longer.

Alinea Health

Venture Round in 2022
Alinea Health is a health-tech startup that provides solutions for corporate health. It utilizes large amounts of data and proprietary algorithms to assist the client company's beneficiaries in navigating their health plans, providing personalized and unbiased guidance, recommendations from the most effective doctors in the accredited network, and conveniences such as scheduling consultations and exams. In addition to continuous monitoring, its doctors use the Lifestyle Medicine methodology to promote a healthy lifestyle and lower the risk of developing chronic diseases.

Homeward

Series A in 2022
Homeward is rearchitecting rural health and care for the 60 million Americans living in rural communities. Homeward employs a multidisciplinary care team, available both virtually and on the ground via mobile care units, with in-home remote monitoring to better connect patients to high-quality, affordable, and comprehensive care. Today, the company partners with Medicare Advantage plans, taking on the full risk of their members to improve outcomes and reduce costs.

Ro

Venture Round in 2022
Ro is a telehealth company established in New York City in 2017, specializing in digital health clinics that cater to both men's and women's health, as well as smoking cessation. It offers a patient-centric healthcare system that integrates primary care services, diagnostics, and pharmacy solutions. The platform facilitates direct communication between patients and physicians, providing an end-to-end healthcare experience that encompasses diagnosis, medication delivery, and ongoing care management. Ro's services include personalized treatment options for issues such as erectile dysfunction and smoking cessation, all designed to enhance accessibility and affordability without relying on insurance. The company operates a nationwide provider network, incorporates an in-home care API, and utilizes proprietary pharmacy distribution centers to streamline healthcare services for its users.

Dewpoint Therapeutics

Series C in 2022
Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.

Jasper Health

Series A in 2022
Jasper Health is a digital platform based in Boise, Idaho, that provides psychosocial support to cancer patients through telemedicine and a personalized planning application known as the Cancer Care Companion. Founded in 2018, the platform enables users to connect with caregivers, healthcare providers, and support teams from employers and health plans. Its smart application features tools for organizing appointments, tracking symptoms, side effects, and moods, as well as curating necessary products. This comprehensive approach helps patients stay organized while activating support from family and friends, enhancing their overall care experience. Jasper Health serves tens of thousands of members, focusing on personalized support tailored to the unique challenges faced by individuals living with cancer.

Transcarent

Series C in 2022
Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Maze Therapeutics

Venture Round in 2022
Maze Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative medicines that leverage the effects of rare genetic variants to address unmet medical needs. Founded in 2017 and originally known as Modulus Therapeutics, the company utilizes its proprietary Compass platform to identify genetic variants linked to diseases and map them to the biological pathways that drive these conditions in specific patient populations. By integrating large-scale human genetics data and functional genomics with various drug discovery methods, Maze Therapeutics aims to reveal modifier genes that offer protective benefits. This approach enhances the understanding of target biology and informs the development of novel therapies, ultimately enabling pharmaceutical companies to create effective treatments.

Overjet

Series B in 2021
Overjet, Inc. specializes in developing artificial intelligence (AI) software aimed at enhancing dental care. Founded by experts from MIT and Harvard, the company produces clinical optimization and utilization software that analyzes dental clinical data to assess practice performance and identify growth opportunities. Its AI technology is designed to automatically review claims, highlighting instances of over and underutilization to ensure appropriate care at reduced costs. Overjet's FDA-cleared platform is the first objective standard for oral health decision-making, enabling dentists to detect pathologies accurately and communicate effectively with patients. Established in 2018, Overjet is headquartered in Allston, Massachusetts.

Cadence Solutions

Series B in 2021
Cadence is a pioneering health technology company helping the nation’s largest health systems deliver world-class care outside of the four walls of the hospital.

Ophelia

Series B in 2021
Ophelia offers medication and support for quitting opioids. They are a diverse collection of hearts and minds - doctors, scientists, techies, and citizens - on a mission to offer the best of medicine without the baggage of rehab. They are driven by science, committed to privacy, and bound to the client's right to make their own choices. They believe in recommendations, not orders. It was founded in 2019 and is based in New York, New York.

Sword Health

Series D in 2021
Sword Health is a digital health company focused on revolutionizing physical rehabilitation through its advanced artificial intelligence care platform. The company aims to alleviate pain for billions of people by providing a unique solution that combines the expertise of physical therapy professionals with an interactive AI experience. This platform enables patients to access customized rehabilitation exercises from their homes, allowing them to receive supervised care anytime and anywhere. Sword Health's approach not only enhances patient independence but also offers valuable data to clinical teams and decision-makers, ultimately improving clinical and cost-saving outcomes in the field of physical therapy.

Variant Bio

Series B in 2021
Variant Bio Inc. is a biotechnology company based in Seattle, Washington, that focuses on developing therapeutics through the study of human genetic diversity. Founded in 2018, the company identifies individuals and populations that exhibit extreme traits of medical significance, utilizing advanced sequencing technologies and analytic methods to uncover the genes and pathways associated with these traits. By leveraging insights from genetic research, Variant Bio aims to discover new therapeutic targets for conditions such as neurodegenerative, autoimmune, and cardiometabolic diseases. The company's innovative approach combines statistical genetics and machine learning, enhancing the potential for genomic drug discovery to address unmet medical needs.

Zerigo Health

Series B in 2021
Clarify Medical is innovating a well-established treatment, UVB therapy, to become easier, more convenient, more empowering, and more connected for psoriasis, eczema and vitiligo patients. The company also focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions. Clarify Medical indicated for the localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology and Vitiligo Working Group. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction.

Better Health

Series A in 2021
Better Health is a support and supplies platform designed to improve the management of chronic conditions such as ostomy, chronic wounds, diabetes, chronic retention, and incontinence through peer-to-peer connections. The platform offers expert guidance to help patients select and use the appropriate medical supplies while providing education and support to enhance engagement and adherence to treatment. This approach is endorsed by healthcare payers and providers, leading to better health outcomes, reduced overutilization of services, and improved mental health for users. Better Health operates across 48 states and collaborates with major payers, including Medicare, Medicaid, and several private insurers. The platform boasts a high customer satisfaction rating of 98%, reflecting its effectiveness in modernizing the medical supplies industry and lowering healthcare costs for insurers and patients alike.

Devoted

Series D in 2021
Devoted Health is a healthcare company focused on enhancing the health and well-being of older Americans by treating each individual with care and compassion. The company offers an integrated healthcare solution that includes Medicare Advantage plans, access to local providers, and the option for virtual and in-home care through Devoted Medical. Their approach includes personalized medical plans and dedicated guides who work closely with physicians to streamline care and minimize unnecessary procedures. By leveraging advanced technology and a robust network of healthcare professionals, Devoted Health aims to provide high-quality, tailored healthcare services to its members.

Loop

Series A in 2021
By using data, technology, and high quality medical expertise, we aim to deliver an empathetic people-centric healthcare experience that helps people live longer.

Overjet

Series A in 2021
Overjet, Inc. specializes in developing artificial intelligence (AI) software aimed at enhancing dental care. Founded by experts from MIT and Harvard, the company produces clinical optimization and utilization software that analyzes dental clinical data to assess practice performance and identify growth opportunities. Its AI technology is designed to automatically review claims, highlighting instances of over and underutilization to ensure appropriate care at reduced costs. Overjet's FDA-cleared platform is the first objective standard for oral health decision-making, enabling dentists to detect pathologies accurately and communicate effectively with patients. Established in 2018, Overjet is headquartered in Allston, Massachusetts.

Cadence Solutions

Series A in 2021
Cadence is a pioneering health technology company helping the nation’s largest health systems deliver world-class care outside of the four walls of the hospital.

Aidoc

Series C in 2021
Aidoc is a company based in Tel Aviv, Israel, specializing in artificial intelligence solutions for healthcare, particularly in the field of medical imaging. Founded in 2016, Aidoc has developed a platform that enhances the efficiency of radiologists by analyzing medical scans immediately after they are performed. Its AI-driven technology identifies critical anomalies and suggests the prioritization of time-sensitive pathologies, enabling healthcare professionals to respond swiftly and effectively. This approach helps to reduce turnaround times, decrease hospital stays, and ultimately improve patient outcomes. Aidoc's decision support software leverages deep learning algorithms to assist radiologists in making accurate diagnoses, thereby transforming the medical imaging process.

Osmind

Series A in 2021
Osmind is a San Francisco-based public benefit corporation focused on enhancing mental health care through innovative technology and scientific research. The company develops a specialized mental health operating platform that caters to clinicians and researchers working on new treatments for moderate to severe mental health conditions. Its electronic health record technology is tailored for interventional treatment workflows, featuring tools for patient journaling and support with health plan reimbursement. By providing these resources, Osmind aims to empower healthcare professionals to explore novel therapeutic approaches, precision psychiatry, and improve patient care outcomes.

Sword Health

Series C in 2021
Sword Health is a digital health company focused on revolutionizing physical rehabilitation through its advanced artificial intelligence care platform. The company aims to alleviate pain for billions of people by providing a unique solution that combines the expertise of physical therapy professionals with an interactive AI experience. This platform enables patients to access customized rehabilitation exercises from their homes, allowing them to receive supervised care anytime and anywhere. Sword Health's approach not only enhances patient independence but also offers valuable data to clinical teams and decision-makers, ultimately improving clinical and cost-saving outcomes in the field of physical therapy.

Transcarent

Series B in 2021
Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

PathAI

Series C in 2021
PathAI, Inc. is a company that develops artificial intelligence-based technology solutions aimed at enhancing the accuracy and efficiency of pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI's platform utilizes machine and deep learning techniques to process large datasets, enabling pathologists to diagnose cancer and other conditions rapidly and accurately. The technology not only assists in making precise diagnoses but also identifies patients who may benefit from innovative therapies, thereby facilitating personalized medicine. PathAI addresses complex challenges in pathology for both the research and pharmaceutical industries, providing reliable and scalable solutions.

Ophelia

Series A in 2021
Ophelia offers medication and support for quitting opioids. They are a diverse collection of hearts and minds - doctors, scientists, techies, and citizens - on a mission to offer the best of medicine without the baggage of rehab. They are driven by science, committed to privacy, and bound to the client's right to make their own choices. They believe in recommendations, not orders. It was founded in 2019 and is based in New York, New York.

Oath Care

Seed Round in 2021
Oath Care is developing an innovative model of group-based, continuous healthcare aimed at enhancing health outcomes for children. The company operates an online platform that connects medical providers with families, fostering intimate connections and shared parental experiences. Through this platform, users can access specialist support and guidance via group chats and one-on-one video calls. This approach allows patients to receive tailored medical and emotional support, addressing their individual needs effectively.

Ro

Series D in 2021
Ro is a telehealth company established in New York City in 2017, specializing in digital health clinics that cater to both men's and women's health, as well as smoking cessation. It offers a patient-centric healthcare system that integrates primary care services, diagnostics, and pharmacy solutions. The platform facilitates direct communication between patients and physicians, providing an end-to-end healthcare experience that encompasses diagnosis, medication delivery, and ongoing care management. Ro's services include personalized treatment options for issues such as erectile dysfunction and smoking cessation, all designed to enhance accessibility and affordability without relying on insurance. The company operates a nationwide provider network, incorporates an in-home care API, and utilizes proprietary pharmacy distribution centers to streamline healthcare services for its users.

Ossium Health

Series B in 2021
Ossium Health, Inc. is engaged in the development and manufacturing of cell therapy products aimed at treating leukemia, other blood cancers, and tissue damage, as well as addressing radiation poisoning. The company offers a range of innovative therapies, including HPC, Marrow, which features HLA-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients; Chimera, which enhances organ transplantation; and Chymalis, composed of mesenchymal stem cells that promote the healing of damaged bone and muscle tissue. Additionally, Ossium provides bone marrow cells for research purposes in oncology and immunology. Founded in 2016 and headquartered in San Francisco, California, Ossium Health focuses on improving health outcomes and longevity through advanced bioengineering techniques.

Plume Clinic

Series A in 2021
Plume is a health tech company for the transgender community. The company focuses on radically increasing access to care, medication, and products for the trans community, supporting a bold, authentic and healthy lifestyle. Its vision is to make gender-affirming care available to anyone until it transforms healthcare for every trans life.

Elephant Healthcare

Series A in 2021
Elephant Healthcare Limited, founded in 2018 and based in London, develops a digital health system aimed at revolutionizing global healthcare. The company constructs a global digital health network that links various components of the healthcare ecosystem. Founded by medical professionals, Elephant leverages technological innovations to tackle significant challenges in healthcare, focusing on cost reduction and improving patient outcomes. Its software platform digitizes medical clinics, fostering connectivity and providing tools to enhance primary care. Additionally, the platform utilizes blockchain and decentralized infrastructure to integrate existing services and facilitate the development of new health applications, particularly benefiting hospitals serving low-income populations.

Curai Health

Series B in 2020
Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company leverages artificial intelligence to provide chat-based primary care services, aiming to make high-quality and affordable healthcare accessible to everyone, anytime. Curai Health's platform integrates clinicians with advanced AI and machine learning tools to create a learning healthcare system that enhances the efficiency and cost-effectiveness of medical care. By facilitating better communication between patients and healthcare professionals, the platform aids in accurate diagnosis and treatment. Curai Health offers its services directly to consumers and through partnerships with enterprises.

Story Health

Seed Round in 2020
Story Health Corporation, founded in 2020 and based in Saratoga, California, develops advanced virtualized clinical care software tools aimed at aiding healthcare specialists, particularly neurologists and primary care physicians. The company offers a comprehensive healthcare technology platform that includes virtual patient programs, therapy management, and analytics designed to bridge the gap between clinical evidence and patient experiences. By utilizing data from high-frequency sources, Story Health empowers clinicians to better understand medical situations and make informed decisions regarding the physiological impacts of diseases and therapies. Through its innovative approach, Story Health enhances the ability of specialists to deliver effective patient care.

Transcarent

Series A in 2020
Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Osmind

Seed Round in 2020
Osmind is a San Francisco-based public benefit corporation focused on enhancing mental health care through innovative technology and scientific research. The company develops a specialized mental health operating platform that caters to clinicians and researchers working on new treatments for moderate to severe mental health conditions. Its electronic health record technology is tailored for interventional treatment workflows, featuring tools for patient journaling and support with health plan reimbursement. By providing these resources, Osmind aims to empower healthcare professionals to explore novel therapeutic approaches, precision psychiatry, and improve patient care outcomes.

Ro

Series C in 2020
Ro is a telehealth company established in New York City in 2017, specializing in digital health clinics that cater to both men's and women's health, as well as smoking cessation. It offers a patient-centric healthcare system that integrates primary care services, diagnostics, and pharmacy solutions. The platform facilitates direct communication between patients and physicians, providing an end-to-end healthcare experience that encompasses diagnosis, medication delivery, and ongoing care management. Ro's services include personalized treatment options for issues such as erectile dysfunction and smoking cessation, all designed to enhance accessibility and affordability without relying on insurance. The company operates a nationwide provider network, incorporates an in-home care API, and utilizes proprietary pharmacy distribution centers to streamline healthcare services for its users.

Ophelia

Seed Round in 2020
Ophelia offers medication and support for quitting opioids. They are a diverse collection of hearts and minds - doctors, scientists, techies, and citizens - on a mission to offer the best of medicine without the baggage of rehab. They are driven by science, committed to privacy, and bound to the client's right to make their own choices. They believe in recommendations, not orders. It was founded in 2019 and is based in New York, New York.

Karius

Series B in 2020
Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

PathAI

Series B in 2019
PathAI, Inc. is a company that develops artificial intelligence-based technology solutions aimed at enhancing the accuracy and efficiency of pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI's platform utilizes machine and deep learning techniques to process large datasets, enabling pathologists to diagnose cancer and other conditions rapidly and accurately. The technology not only assists in making precise diagnoses but also identifies patients who may benefit from innovative therapies, thereby facilitating personalized medicine. PathAI addresses complex challenges in pathology for both the research and pharmaceutical industries, providing reliable and scalable solutions.

Curai Health

Series A in 2018
Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company leverages artificial intelligence to provide chat-based primary care services, aiming to make high-quality and affordable healthcare accessible to everyone, anytime. Curai Health's platform integrates clinicians with advanced AI and machine learning tools to create a learning healthcare system that enhances the efficiency and cost-effectiveness of medical care. By facilitating better communication between patients and healthcare professionals, the platform aids in accurate diagnosis and treatment. Curai Health offers its services directly to consumers and through partnerships with enterprises.

Ro

Seed Round in 2017
Ro is a telehealth company established in New York City in 2017, specializing in digital health clinics that cater to both men's and women's health, as well as smoking cessation. It offers a patient-centric healthcare system that integrates primary care services, diagnostics, and pharmacy solutions. The platform facilitates direct communication between patients and physicians, providing an end-to-end healthcare experience that encompasses diagnosis, medication delivery, and ongoing care management. Ro's services include personalized treatment options for issues such as erectile dysfunction and smoking cessation, all designed to enhance accessibility and affordability without relying on insurance. The company operates a nationwide provider network, incorporates an in-home care API, and utilizes proprietary pharmacy distribution centers to streamline healthcare services for its users.

PathAI

Series A in 2017
PathAI, Inc. is a company that develops artificial intelligence-based technology solutions aimed at enhancing the accuracy and efficiency of pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI's platform utilizes machine and deep learning techniques to process large datasets, enabling pathologists to diagnose cancer and other conditions rapidly and accurately. The technology not only assists in making precise diagnoses but also identifies patients who may benefit from innovative therapies, thereby facilitating personalized medicine. PathAI addresses complex challenges in pathology for both the research and pharmaceutical industries, providing reliable and scalable solutions.

Commure

Seed Round in 2017
Commure, Inc. is a technology company that develops an open platform aimed at healthcare software developers, enabling the creation and deployment of advanced healthcare applications. The platform is built on the open HL7 FHIR standard and offers various features, including an FHIR API server, security framework, event service bus, EHR integration, and a flexible data store. Commure's solutions facilitate the unification of disparate datasets, providing meaningful insights and enhancing performance through intuitive applications. The company collaborates with health systems, digital innovators, and payors to foster a vibrant healthcare ecosystem, ultimately empowering clinicians and staff to improve patient care. Established in 2017, Commure is headquartered in San Francisco, California, with additional offices in Boston, Montreal, and Bogota.

Corvia

Series D in 2014
Corvia Medical is a medical device company based in Andover, Massachusetts, established in 2009. The company specializes in developing innovative solutions for heart failure, particularly through its InterAtrial Shunt Device (IASD). This transcatheter device is designed to address diastolic heart failure, also known as heart failure with preserved ejection fraction. The IASD works by creating a small opening between the left and right atria, which helps to lower blood pressure in the left atrium and lungs. This reduction in pressure aims to alleviate symptoms and slow the progression of heart failure, allowing patients to maintain a healthier lifestyle and reduce their risk of severe heart-related complications.

Corvia

Series C in 2013
Corvia Medical is a medical device company based in Andover, Massachusetts, established in 2009. The company specializes in developing innovative solutions for heart failure, particularly through its InterAtrial Shunt Device (IASD). This transcatheter device is designed to address diastolic heart failure, also known as heart failure with preserved ejection fraction. The IASD works by creating a small opening between the left and right atria, which helps to lower blood pressure in the left atrium and lungs. This reduction in pressure aims to alleviate symptoms and slow the progression of heart failure, allowing patients to maintain a healthier lifestyle and reduce their risk of severe heart-related complications.

SynapDx

Series B in 2012
SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.

Aidin

Venture Round in 2012
Aidin is a healthcare technology company focused on enhancing the discharge planning process for hospitals and social workers. Its platform streamlines the workflow for discharge planning professionals by automating the generation of provider listings, thereby minimizing administrative tasks and allowing social workers to concentrate more on patient care. Aidin provides patients with access to quality ratings and reviews of available post-acute care providers, facilitating informed decision-making. The platform also tracks patient experiences and outcomes, equipping case managers with valuable insights to identify the most effective providers for specific health conditions. By connecting patients with the right post-hospital care options, Aidin aims to reduce readmissions and improve overall patient satisfaction.

Humedica

Venture Round in 2012
Humedica is a clinical intelligence company that specializes in health analytics, providing tools for hospitals, physicians, and life sciences organizations. The company's primary offering, Humedica MinedShare, is a platform designed to transform unconnected data from various sources into actionable insights, enabling clients to make better-informed decisions. By facilitating clinical, operational, and financial benchmarking across the continuum of care, Humedica supports healthcare providers in enhancing the quality and efficiency of their services.

OvaScience

Series B in 2012
OvaScience, Inc. was a fertility company focused on developing innovative treatments for women facing infertility challenges. The company was founded in 2011 and was headquartered in Waltham, Massachusetts. OvaScience specialized in proprietary technology derived from the discovery of egg precursor (EggPC) cells, which allowed for the enhancement of egg quality and improved outcomes in in vitro fertilization (IVF). Their treatment options included OvaPrime, which aimed to restore a woman's egg production using her own EggPC cells, OvaTure, designed to mature these cells into fertilizable eggs outside the body, and AUGMENT, which utilized mitochondria from EggPC cells to enhance fertilization and pregnancy rates. The company also explored OvaXon for preventing inherited diseases. OvaScience was co-founded by a team of experts from Harvard Medical School and was backed by prominent life science investors. In December 2018, OvaScience was acquired by Millendo Therapeutics in a reverse merger.

Humedica

Venture Round in 2011
Humedica is a clinical intelligence company that specializes in health analytics, providing tools for hospitals, physicians, and life sciences organizations. The company's primary offering, Humedica MinedShare, is a platform designed to transform unconnected data from various sources into actionable insights, enabling clients to make better-informed decisions. By facilitating clinical, operational, and financial benchmarking across the continuum of care, Humedica supports healthcare providers in enhancing the quality and efficiency of their services.

SynapDx

Series A in 2010
SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.

Humedica

Series A in 2009
Humedica is a clinical intelligence company that specializes in health analytics, providing tools for hospitals, physicians, and life sciences organizations. The company's primary offering, Humedica MinedShare, is a platform designed to transform unconnected data from various sources into actionable insights, enabling clients to make better-informed decisions. By facilitating clinical, operational, and financial benchmarking across the continuum of care, Humedica supports healthcare providers in enhancing the quality and efficiency of their services.

Imprivata

Series C in 2008
Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.

MovingHealth

Seed Round in 2007
Movinghealth, Inc. provides Web based health care services to patients and consumers. The company offers wellbeing news and articles, medical reference content databases, and online therapeutic remedial imagery and graphics. Movinghealth was founded in 2007 and is based in Cambridge, Massachusetts.

Imprivata

Series B in 2006
Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.

Imprivata

Series A in 2005
Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.

Imprivata

Series A in 2002
Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.